/* Add some basic styling to make the post more readable */
body {
font-family: Arial, sans-serif;
margin: 20px;
}
section {
margin-bottom: 20px;
}
h1 {
font-weight: bold;
font-size: 24px;
margin-top: 0;
}
h2 {
font-size: 18px;
margin-top: 10px;
}
The Uterine Fibroid Intervention and Gynecological Health Treatment Act of 2025
HR 4392 IH – 119th Congress (2nd Session)
SIGNATURES
Ms. BROWN (for herself, Ms. C LARKE of New York, Ms. S EWELL , Mrs.
FOUSHEE , Ms. M CC LELLAN , Ms. V ELA
ZQUEZ , Mr. F IELDS , Ms. K ELLY
of Illinois, Mrs. DINGELL , Ms. TLAIB , Mrs. TRAHAN , Mr. JOHNSON of Georgia, Ms. A
ANSARI , Mrs. WATSON COLEMAN , Mr. DAVID S COTT of Georgia, Mr. T HANEDAR , Mr.
THOMPSON of Mississippi, Mr.
K RISHNAMOORTHI , Ms. SALINAS , Mrs. MCIVER , Mr. CARTER of Louisiana, Ms. M
ENG , Ms. WILSON of Florida, Ms. LEE of Pennsylvania, Ms.
SIMON , Ms. WASSERMAN SCHULTZ , Mr. FIGURES , Ms. A DAMS , Mr.
K HANNA , Ms. UNDERWOOD , Mr. GREEN of Texas, Ms. TOKUDA , Ms.
RIVAS , Mr. MANNION , Ms. PRESSLEY , Ms. TITUS , and Mr. LATIMER )
SECTION 1. SHORT TITLE
This Act may be cited as the ‘‘Uterine Fibroid Intervention and Gynecological Health Treatment Act of
2025’’.
SEC. 2. RESEARCH ON UTERINE FIBROID EARLY DETECTION AND INTERVENTION
- (a) IN GENERAL.—The Secretary of Health and Human Services (in this Act referred to as the ‘‘Secretary’’)
shall—- conduct or support research on increasing early detection of, and intervention for,
uterine fibroids; - based on the results of such research and other relevant information, formulate evidence-based
or evidence-informed strategies to increase early detection in health care settings.
- conduct or support research on increasing early detection of, and intervention for,
- (b) TIMELINE.—The Secretary shall finalize the evidence-based or evidence-informed strategies required
by subsection (a)(2) as expeditiously as possible in order to make such strategies available to grantees under
section 3 to implement such strategies pursuant to section 3(b)(3).
SEC. 3. GRANTS WITH RESPECT TO UTERINE FIBROID EARLY DETECTION AND INTERVENTION
- (a) IN GENERAL.—The Secretary of Health and Human Services (in this Act referred to as the ‘‘Secretary’’)
may award grants to States for carrying out programs—- to increase early detection of and intervention for uterine fibroids;
- to develop and implement public awareness and education campaigns for the early detection and
intervention of uterine fibroids.
- (b) USE OF FUNDS.—A State receiving a grant under this section may use the grant, with respect to increasing
early detection of and intervention for uterine fibroids, for the following activities: - Screening procedures, including advanced gynecological imaging (including payment therefor).
- Patient navigation services.
- Implementation of evidence-based or evidence-informed strategies proven to increase early detection in
health care settings. - Facilitating access to health care settings.
SEC. 4. RESEARCH WITH RESPECT TO UTERINE FIBROID EARLY DETECTION AND INTERVENTION
The Secretary may award grants to conduct research, which may include clinical trials, related to—
- disparities in pain control and management in uterine fibroid surgical treatment;
- Asherman’s Syndrome, intrauterine adhesions, and other intrauterine conditions as determined appropriate by the Secretary.
SEC. 5. REPORTS TO CONGRESS
- (a) REPORTS ON GRANTS.—Not later than 2 years after the initial award of grants under this Act, and
every 2 years thereafter, the Secretary shall submit to the Congress, and make publicly available on the
appropriate website of the Department of Health and Human Services, a report summarizing the findings and
results of programs and activities funded through grants under this Act. - (b) REPORT ON RESEARCH DEVELOPMENTS.—Not later than 2 years after the date of enactment of this Act,
and every 2 years thereafter, the Secretary shall submit to the Congress, and make publicly available on the
appropriate website of the Department of Health and Human Services, a report outlining research developments
and findings related to— - disparities in pain control and management in uterine fibroid surgical treatment;
- Asherman’s Syndrome, intrauterine adhesions, and other intrauterine conditions as determined appropriate
by the Secretary.